You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康方生物-B(09926.HK)股價異動 各項業務發展一切正常
格隆匯 01-06 06:14

格隆匯1月6日丨康方生物-B(09926.HK)發佈公吿,董事會已獲悉公司股份於2022年1月5日出現股價及成交量不尋常波動。經做出一切有關公司於合理情況下的查詢後,公司確認,其並不知悉任何根據香港法例第571章證券及期貨條例第XIVA部須予披露的資料。

公司特此澄清,公司目前各項業務發展一切正常,公司對未來的發展和中國生物醫藥行業的發展充滿信心。自新一輪藥政改革以來,得益於中國藥物創新綜合環境的全面改善,中國生物醫藥行業進入了創新發展的新時代,一批新興生物藥物創新公司的崛起,推動中國生物製藥產業迅速提升,向國際水平靠攏。企業研發緊隨科學前沿,國際熱門靶點的快速跟進,部分龍頭企業加速原研創新,每年新藥獲批數量和速度不斷提升,對外合作和產品授權等海外交易數量不斷增多,行業和企業的價值亦隨之持續增長。

公司始終以臨牀價值為中心,面向全球市場自主創新。自2012年成立至今,公司通過完全自主研發建立起擁有超過30多個臨牀前和臨牀階段項目的豐富產品組合,包括多個全球首創新藥項目,四個項目被評為“中國醫藥生物技術十大進展”,PD-1/CTLA-4更是在全球形成突破,2021年成為第一個遞交新藥上市申請的基於PD-1的雙抗項目,並獲優先審評。

截至該公吿日期,公司並不知悉任何可能對業務運營、未來臨牀研究國內外審批造成重大不利影響的監管制度的變動。公司謹此提醒股東及有意投資者理性對待任何非由公司正式刊發的消息,股東及有意投資者在買賣股份時務請謹慎行事。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account